| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2008.02.072 |
| P698 | PubMed publication ID | 18502003 |
| P50 | author | Alexandre Harari | Q43779462 |
| Wolfgang Stöhr | Q86907024 | ||
| Giuseppe Pantaleo | Q88061163 | ||
| Jonathan L. Heeney | Q39066258 | ||
| P2093 | author name string | Jonathan Weber | |
| Ralf Wagner | |||
| Cristina Cellerai | |||
| Christiane Moog | |||
| Abdel Babiker | |||
| Elizabeth Brodnicki | |||
| Sheena McCormack | |||
| Tristan Barber | |||
| Jim Tartaglia | |||
| Donatella Ciuffreda | |||
| Pierre-Alexandre Bart | |||
| Hans Wolf | |||
| Ken Legg | |||
| Séverine Burnet | |||
| Marie-Joëlle Frachette | |||
| Miranda Cowen | |||
| Romilda Gamboni | |||
| P2860 | cites work | EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. | Q54454033 |
| Estimating the benefit of an HIV-1 vaccine that reduces viral load set point | Q79580562 | ||
| Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages | Q80967901 | ||
| Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial | Q21144715 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial | Q29619176 | ||
| Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial | Q29619179 | ||
| Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients | Q33852361 | ||
| An HIV vaccine--evolving concepts | Q34629012 | ||
| Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses | Q36229406 | ||
| An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses | Q36446900 | ||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 3162-3174 | |
| P577 | publication date | 2008-05-06 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone | |
| P478 | volume | 26 |
| Q37656908 | A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes |
| Q26851165 | A brief history of the global effort to develop a preventive HIV vaccine |
| Q21135240 | A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses |
| Q35628697 | A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations |
| Q34593969 | A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects |
| Q36391900 | A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication |
| Q28482252 | Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine |
| Q37277825 | Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial |
| Q37221660 | Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults |
| Q36697992 | Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania |
| Q37799412 | Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans |
| Q39992443 | Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens |
| Q38184579 | Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines |
| Q30364312 | Developments in HIV-1 immunotherapy and therapeutic vaccination. |
| Q59360867 | Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors |
| Q33489847 | Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. |
| Q36978452 | Enhancing poxvirus vectors vaccine immunogenicity. |
| Q37590335 | Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity |
| Q34342558 | HIV vaccines: lessons learned and the way forward |
| Q35140001 | HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial |
| Q40339467 | HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci |
| Q35914311 | Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates |
| Q36302688 | Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice |
| Q47252143 | Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways |
| Q27320923 | Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions |
| Q50043326 | Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates |
| Q45031334 | Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation |
| Q27489413 | Improved Efficacy of a Gene Optimised Adenovirus-based Vaccine for Venezuelan Equine Encephalitis Virus |
| Q28742751 | Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors |
| Q38009870 | Improved outlook on HIV-1 prevention and vaccine development |
| Q28744555 | In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers |
| Q34309830 | Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. |
| Q34816639 | Lessons drawn from recent HIV vaccine efficacy trials |
| Q104486611 | Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques |
| Q64074435 | Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques |
| Q26861148 | Nonhuman primate models for HIV/AIDS vaccine development |
| Q33693891 | Nonreplicating vectors in HIV vaccines |
| Q33645528 | Novel directions in HIV-1 vaccines revealed from clinical trials |
| Q30378897 | Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. |
| Q34487151 | Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120. |
| Q30977303 | Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine |
| Q33527383 | Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine |
| Q34772727 | Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles |
| Q33749950 | Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate |
| Q36736400 | Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens |
| Q26995078 | Poxvirus vectors as HIV/AIDS vaccines in humans |
| Q59351003 | Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost |
| Q28485174 | Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review |
| Q35943846 | Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice |
| Q59351008 | Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC |
| Q34589611 | Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers |
| Q36668517 | Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. |
| Q38484762 | Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). |
| Q90637089 | Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial |
| Q33875160 | Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. |
| Q26770839 | Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective |
| Q36119504 | Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants |
| Q35868091 | Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine |
| Q34247289 | Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. |
| Q38725610 | The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. |
| Q26995905 | The evolution of poxvirus vaccines |
| Q34077543 | The influence of delivery vectors on HIV vaccine efficacy |
| Q37548329 | Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. |
| Q24602593 | Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients |
| Q41039943 | Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax |
| Q35571248 | Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. |
| Q34991112 | Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. |
Search more.